Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis

Comparative Study of the Efficacy and Safety of Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis: A Pilot Randomized Controlled Clinical Trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07713212

Enrollment

Registered

2026-07-20

Start date

2026-08-15

Completion date

2027-02-15

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

psoriasis, fractional CO2 laser, topical treatment

Brief summary

To assess whether adding fractional laser to topical corticosteroid improves treatment outcomes in palmoplanter psoriasis compared to topical corticosteroid alone.

Detailed description

· To evaluate and compare the reduction in disease severity of palmoplantar psoriasis using the Palmoplantar Psoriasis Area and Severity Index (PPPASI) in both treatment groups

Interventions

DEVICEFractional CO2 laser assisted drug delivery

Sessions of fractional CO2 every 4 weeks with application of topical steroids

DRUGTopical Corticosteroid (TCS)

Daily application of topical corticosteroids on palmoplantar psoriasis

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Adults aged ≥18 years * Stable psoriasis * Confirmed cases of palmoplantar psoriasis (with or without psoriasis elsewhere) dermoscopically(Hand \_held dermoscopy) and histopathologically if required. * Willingness to comply with treatment and follow-up * Written informed consent obtained

Exclusion criteria

* Other palmoplantar dermatoses (eczema, tinea, keratoderma) * Generlized Pustular psoriasis * Erythrodermic psoriasis * Use of: * Systemic antipsoriatic therapy within 3 months * Biologic therapy within 12 weeks * Topical treatment on palms/soles within 2 weeks * Pregnancy or lactation * History of photosensitivity disorders

Design outcomes

Primary

Measure	Time frame	Description
Improvement in Palmoplantar Psoriasis Severity Index (ppPASI) by topical corticosteroids only vs fractional CO₂ laser-assisted delivery of topical corticosteroids	3 month	The primary outcome will be the change in the Palmoplantar Psoriasis Severity Index (ppPASI) score from baseline to the end of treatment (at Week 12). The ppPASI assesses disease severity based on erythema, scaling, and induration/infiltration of the palms and soles, in addition to the affected surface area. Scores range from 0 to 72, with higher scores indicating more severe disease. Treatment success: Achievement of ppPASI-50, ppPASI-75, and ppPASI-90 (≥50%, ≥75%, and ≥90% reduction from baseline).

Secondary

Measure	Time frame	Description
Physician Global Assessment (PGA)	3 months	Clinical improvement will be assessed using the Physician Global Assessment for palmoplantar psoriasis. The PGA is a 5- or 6-point scale: 0 = Clear 1. = Almost clear 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe (if using the 6-point scale)

Countries

Egypt

Contacts

CONTACTAmira M Elbendary, MD

aelbendary@kasralainy.edu.eg+201555668584

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 21, 2026